Vargatef

News

Boehringer Ingelheim is the latest company to gain a Promising Innovative Medicine (PIM) status in the UK for one of its drugs.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.